Abstract #1909
Engineering of a MRI Theranostic Agent for Detection and Treatment of Cerebrovascular Amyloid
Jens T Rosenberg 1,2 , Kristen MJ Ahlschwede 3,4 , Edward K Agyare 5 , Geoffery L Curran 4 , Samuel C Grant 1,2 , and Karunya K Kandimalla 3,4
1
National High Magnetic Field Laboratory,
Florida State University, Tallahassee, FL, United
States,
2
Chemical
& Biomedical Engineering, Florida State University,
Tallahassee, FL, United States,
3
Pharmaceutics
and Brain Barriers Research Center, University of
Minnesota, Minneapolis, MN, United States,
4
Neurology,
Neuroscience and Biochemistry/Molecular Biology, Mayo
Clinic College of Medicine, Rochester, MN, United
States,
5
College
of Pharmacy and Pharmaceutical Science, Florida A&M
University, Tallahassee, FL, United States
This work demonstrates a novel MRI-detectable
multifunctional nanoparticle targeting cerebrovascular
amyloids by conjugating Gd-DTPA with the amyloid
antibody Ig 4.1 while at the same time providing drug
delivery capabilities. This theranostic nanovehicle
shows hypointense contrast for targeted cerebrovascular
amyloids on MR microimages acquired at the ultrahigh
field of 21.1 T. The approach potentially can provide a
heretofore sought after diagnostic and therapeutic tool
for cerebral amyloid angiopathy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
